All In Biotech

Drug Trial Radar · NCT03295396

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

73

Actual

Start

Oct 30, 2017

Primary completion

Dec 31, 2022

Study completion Jul 19, 2023

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Oncoceutics, Inc.
First posted
Sep 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2, open-label, 2-arm study of dordaviprone (ONC201) in patients with recurrent H3 K27M- mutant glioma. The primary assessment of dordaviprone (ONC201) involved evaluating its anti-tumor activity through the overall response rate according to the Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).

Conditions

  • Glioma

Interventions

  • Dordaviprone (ONC201)Drug

    Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Overall ResponseTime frame: From first dose of study treatment through study completion, an average of 1 year

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Stanford Cancer Center

    Stanford, California

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • New York University School of Medicine

    New York, New York

  • Columbia University

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.